Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | EDNRA | P25101 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356271 | 0.86 | TAAR1 (0.50) | ALDH1A1LMNACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5354260 | 0.82 | KCNH2 (0.45) | ALDH1A1LMNAKCNH2CYP1A2CYP2D6 | |
| SCHEMBL5356350 | 0.80 | LMNA (0.54) | ALDH1A1LMNAKCNH2CYP1A2CYP2D6 | |
| SCHEMBL12293577 | 0.79 | MAPT (0.65) | ALDH1A1LMNAKCNH2CYP1A2CYP2D6 | |
| SCHEMBL5358993 | 0.78 | KCNH2 (0.41) | ALDH1A1LMNAKCNH2CYP1A2CYP2D6 | |
| SCHEMBL19002773 | 0.77 | EDNRA (0.50) | ALDH1A1LMNACYP1A2CYP2C19POLB | |
| SCHEMBL19002770 | 0.77 | EDNRA (0.50) | ALDH1A1LMNACYP1A2CYP2C19POLB | |
| SCHEMBL29164906 | 0.76 | EDNRA (0.51) | ALDH1A1LMNAKCNH2CYP1A2POLB | |
| SCHEMBL19002774 | 0.74 | EDNRA (0.45) | ALDH1A1LMNAKCNH2POLBEDNRA | |
| SCHEMBL11469582 | 0.73 | EDNRA (0.56) | LMNAKCNH2CYP1A2POLBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217723-B2 | Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. | EISAI CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | ALDH1A1 1391/4885LMNA 4744/4885KCNH2 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.